Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors

• المؤلفون الرئيسيون: Sarah Kim (مؤلف), Gezim Lahu (مؤلف), Majid Vakilynejad (مؤلف), Theodoros G. Soldatos (مؤلف), David B. Jackson (مؤلف), Lawrence J. Lesko (مؤلف), Mirjam N. Trame (مؤلف)
• التنسيق: كتاب
• منشور في: Wiley, 2022-06-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Abstract Immunotherapy became a key pillar of cancer therapeutics with the approvals of ipilimumab, nivolumab, and pembrolizumab, which inhibit either cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) or programmed death‐1 (PD‐1) that are negative regulators of T‐cell activation. However, boosting T‐cell ac...